REG - Medpal AI PLC - Placing and WRAP Retail Offer

Medpal AIAnnouncement

Yesterday 16:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260320:nRST5462Xa&default-theme=true

RNS Number : 5462X  Medpal AI PLC  20 March 2026

 

 

20 March 2026

 

MedPal AI Plc

("MedPal AI" or the "Company")

 

Placing and WRAP Retail Offer

 

MedPal AI (AIM: MPAL, FRA: Z1N) the UK digital health and AI company, is
pleased to announce that it has conditionally raised approximately £527,000
("Placing") by way of the issue of 21,080,000 new ordinary shares ("Placing
Shares") at a price of 2.5 pence per share ("Placing Price").  The Placing
Price represents a 13% discount to the closing mid-price of the Company's
ordinary shares on 19 March 2026.

The Company is also offering new ordinary shares to investors via a WRAP
retail offer, which will be announced separately.

The proceeds from the Placing and the WRAP retail offer (together the
"Fundraise") will be used to provide working capital for the Company's
pharmacy operations to enable it to carry both higher levels and a wider range
of stock to meet rising customer demand and also to fund a digital marketing
campaign for MedPal.clinic.

The Placing is conditional on the Placing Shares, which will be issued
credited as fully paid and will rank pari passu in all respects with the
existing Ordinary Shares, being admitted to trading on AIM ("Admission").
Admission of the Placing Shares is expected to occur on or around 26 March
2026.

For the avoidance of doubt, the WRAP retail offer is not part of the Placing.
Completion of the WRAP retail offer is conditional, inter alia, upon the
completion of the Placing but completion of the Placing is not conditional on
the completion of the WRAP retail offer.

 

Total voting rights

Immediately following Admission and excluding any shares to be issued subject
to the WRAP, the Company will have 476,234,640 Ordinary Shares in issue.
Accordingly, the total number of Ordinary Shares in the Company with voting
rights will be 476,234,640. This figure may be used by shareholders in the
Company as denominator for the calculations by which they may determine if
they are required to notify their interest in, or a change to their interest
in, the Company under the Financial Conduct Authority's Disclosure Guidance
and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

 

 MedPal AI plc                       www.medpalplc.com (https://www.medpalplc.com/)

 Jason Drummond

 Cairn Financial Advisers LLP        +44(0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited       +44(0) 20 3869 6080

 Bob Roberts

 Winterflood Retail Access Platform  WRAP@winterflood.com

 Sophia Bechev, Kaitlan Billings     +44(0) 20 3100 0214

 

 

Further information on the Company can be found on its website at
www.medpalplc.com

 

The Company's LEI is 984500EDP8B0A14CBA61.

 

This announcement should be read in its entirety. In particular, the
information in the "Important Notices" section of the announcement should be
read and understood.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEAKKBNABKDNNB



            Copyright 2019 Regulatory News Service, all rights reserved